Gerhard Held

Westpfalz Klinikum — Germany

Medicine · Health Sciences

50h-index9.6kcitations304works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(90), Acute Myeloid Leukemia Research(54), Chronic Lymphocytic Leukemia Research(40), Atmospheric Ozone and Climate(33), CNS Lymphoma Diagnosis and Treatment(32)

Publications304 total

Integration of high-throughput proteomic data and complementary omics layers with PriOmics
Genome Research·2025Open Access
Impact of extranodal involvement in stage I aggressive B-cell lymphoma in the rituximab era: An individual patient data meta-analysis of two Phase III dshnhl/GLA trials
Blood·2025Open Access
Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?
Blood·2025
156 | EXCELLENT OUTCOME WITH INTERIM PET ADAPTED TREATMENT REDUCTION IN ELDERLY DLBCL PTSWITH FAVOURABLE PROGNOSIS: RESULTS OF 288 PTS TREATED IN OPTIMAL > 60 OF THE DSHNHL/GLA
Hematological Oncology·2025Open Access
157 | PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL > 60 TRIAL OF THE DSHNHL/GLA
Hematological Oncology·2025Open Access
64 | NIVOLUMAB + GemOx AS SECOND‐LINE THERAPY FOR PERIPHERAL T CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF A SUB‐COHORT OF THE RANDOMIZED NIVEAU TRIAL
Hematological Oncology·2025Open Access
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity
International Journal of Molecular Sciences·2024· 1 citedOpen Access
Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
Blood·2024
Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL
Blood·2024Open Access
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia
Journal of Clinical Oncology·2024· 14 cited
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma
Annals of Hematology·2024· 3 citedOpen Access
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration
Leukemia·2024· 8 cited
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
Blood Neoplasia·2024· 3 citedOpen Access
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
Journal of Clinical Oncology·2023· 30 cited
R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG
Blood·2023· 9 cited
Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration
Blood·2023· 2 cited
A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration
Blood·2023· 2 cited
A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)
Blood·2023· 4 cited
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
British Journal of Cancer·2023· 6 citedOpen Access
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
HemaSphere·2023· 14 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Konstanze Döhner(17), Hartmut Döhner(17), Richard F. Schlenk(15), Arnold Ganser(15), Katharina S. Götze(15), Verena I. Gaidzik(14), Michael Pfreundschuh(14), Peter Paschka(13), David Nachbaur(10), Michael Lübbert(9), Jürgen Krauter(9), Andrea Kündgen(9), Mark Ringhoffer(9), Gerald Wulf(9), Lars Bullinger(8), Brigitte Schlegelberger(8), Peter Brossart(8), Helmut R. Salih(8), Mohammed Wattad(8), Niels Murawski(8)